Managing anticoagulants in Cardio-Oncology
Cancer and cardiovascular disease (CVD) have shared risk factors and frequently occur together, particularly in elderly...
Therapy
Polypharmacy in the Older Adult CAT Population
During the ICTHIC webinar titled “Challenges in the management of fragile CAT patients (older patient population...
CAT management in older cancer patients
During the ICTHIC webinar, “Challenges in the management of fragile CAT patients (older patient population &...
Twenty years of progress in CAT: an interview with Anna Falanga and Marina Marchetti
The scientific community has shown increased awareness of cancer-associated thrombosis (CAT) over the past two decades....
Immune checkpoint inhibitors and cancer-associated thrombosis: an overview
Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that revolutionized cancer treatment and, in recent...
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
The Impact of DDI on the Cancer Patient
Cancer patients are often prescribed more than one drug and the need to elucidate potential harmful interactions...
What do we know about bleeding risk in patients with cancer?
Venous thromboembolism (VTE) is a well-recognized complication in patients with cancer, with an increase in risk by a...
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...